Skip to main content

Table 3 Cutolo’s NVC patterns, CSURI and VEGF levels in the SSc cohort (n = 44)

From: Nailfold videocapillaroscopy and serum VEGF levels in scleroderma are associated with internal organ involvement

 

Early pattern

Active pattern

Late pattern

CSURI

VEGF-A

Females vs males

6 (14.3 %) vs 0 (0 %)

18 (42.9 %) vs 2 (100 %)

18 (42.9 %) vs 0 (0 %)

9.6 (0.14–80.0) vs 23.2 (19.0–27.5)

0.49 (0.02–3.05) vs 0.25 (0.11–0.38)

Diffuse vs limited

1 (10 %) vs 5 (14.7 %)

5 (50.0 %) vs 15 (44.1 %)

4 (40 %) vs 14 (41.7 %)

9.1 (2.4–50.5) vs 10.5 (0.14–80.0)

0.42 (0.11–3.05) vs 0.49 (0.02–0.07)

Anti-Scl70 vs ACA

0 (0 %) vs 2 (9.1 %)

5 (41.7 %) vs 11 (50 %)

7 (58.3 %) vs 10 (45.4 %)

11.4 (3.6–20.7) vs 11.9 (0.51–80.0)

0.46 (0.13–1.14) vs 0.49 (0.02–1.70)

Anti-Scl70 vs others

0 (0 %) vs 4 (40 %)

5 (41.7 %) vs 4 (40 %)

7 (58.3 %) vs 1 (10 %)

11.4 (2.4–50.5) vs 9.2 (0.14–27.5)

0.46 (0.13–1.14) vs 0.43 (0.02–3.05)

ACA vs others

2 (9.1 %) vs 4 (40 %)

11 (50 %) vs 4 (40 %)

10 (45.4 %) vs 1 (10 %)

11.9 (0.51–80.0) vs 9.2 (0.14–27.5)

0.49 (0.02–1.7) vs 0.43 (0.11–3.05)

No ulcers vs ulcers

3 (10.3 %) vs 2 (13.3 %)

13 (29.5 %) vs 7 (46.7 %)

12 (41.4 %) vs 6 (40 %)

11.9 (0.14–68.7) vs 9.1 (0.51–80.0)

0.47 (0.02–3.05) vs 0.50 (0.11–1.14)

No GE vs GE

2 (22.2 %) vs 4 (11.4 %)

4 (44.4 %) vs 16(45.7 %)

3 (33.3 %) vs 15 (42.5 %)

7.0 (0.51–68.7) vs 12.0 (0.14–80.0)

0.37 (0.13–1.0) vs 0.49 (0.02–3.05)

sPAP < 45

vs > 45 mmHg

6 (14.6 %) vs 0 (0 %)

20 (48.8 %) vs 0 (0 %)

17 (41.4 %) vs 3 (100 %)*

9.9 (0.14–80.0) vs 13 (3.9–15.1)

0.49 (0.02–3.05) vs 0.28 (0.21–0.35)

DLCO < 50 % vs > 50 %

0 (0 %) vs 6 (15.8 %)

2 (33.3 %) vs 18 (47.3 %)

4 (66.6 %) vs 11 (28.9 %)

5.9 (3.9–13.7) vs 11.3 (0.14–80.0)

0.48 (0.28–1.14) vs 0.49 (0.02–3.05)

FVC < 80 % vs > 80 %

0 (0) vs 6 (16.2 %)

3 (42.8 %) vs 17 (45.9 %)

4 (57.1 %) vs 14 (37.8 %)

9.1 (0.14–80.0) vs 13 (3.3–27.5)

0.54 (0.02–3.05) vs 0.38 (0.11–1.0)

No honeycombing vs honeycombing

5 (12.8 %) vs 1 (20 %)

19 (48.7 %) vs 1 (20 %)

15 (38.4 %) vs 3 (60 %)*

5.9 (0.14–80.0) vs 11.8 (5.1–15.1)

0.34 (0.02–3.05) vs 0.68 (0.28–1.14)

Skin score < 14 vs > 14

6 (16.2 %) vs 0 (0 %)

16 (43.2 %) vs 4 (57.1 %)

16 (43.2 %) vs 3 (42.8 %)

10.9 (0.14–80.0) vs 5.5 (2.1–68.7)

0.46 (0.02–1.7) vs 0.52 (0.11–3.05)

No iloprost vs iloprost

3 (15.8 %) vs 3 (12 %)

11 (57.9 %) vs 9 (36 %)

5 (26.3 %) vs 13 (52 %)*

10.5 (0.51–68.7) vs 9.2 (0.14–80.0)

0.38 (0.02–3.05) vs 0.49 (0.13–1.70)

No bosentan vs bosentan

6 (16.2 %) vs 0 (0 %)

19 (51.3 %) vs 1 (14.2 %)

12 (32.4 %) vs 6 (85.7 %)*

10.9 (0.14–80.0) vs 8.3 (3.9–22.3)

0.50 (0.02–3.05) vs 0.28 (0.21–0.58)

Early pattern vs others

–

–

–

4.2 (0.14–11.3) vs 11.2 (0.51–80.0)

0.63 (0.02–0.77) vs 0.39 (0.11–3.05)

Active pattern vs others

–

–

–

5.9 (1.4–68.7) vs 12.1 (0.14–80.0)

0.48 (0.11–3.05) vs 0.43 (0.02–1.07)

Late pattern vs others

–

–

–

13.7 (0.51–80.0) vs 5.9 (0.14–68.7)*

0.35 (0.21–1.70) vs 0.58 (0.02–3.05)

VEGF-A < 0.8U vs > 0.8U

5 (13.5 %) vs 1 (14.3 %)

16 (43.2 %) vs 4 (57.1 %)

16 (43.2 %) vs 2 (28.5 %)

10.2 (0.14–80.0) vs 9.0 (3.3–13.7)

–

CSURI > 2.94 vs < 2.94

4 (11.1 %) vs 2 (25 %)

15 (41.6 %) vs 5 (62.5 %)

17 (47.2 %) vs 1 (12.5 %)*

–

0.46 (0.02–3.05) vs 0.58 (0.13-0.71)

  1. anti-Scl70 anti-topoisomerase I, CSURI capillaroscopic skin ulcer risk index, D diffuse, DLCO carbon monoxide diffusing capacity, FVC forced vital capacity, L limited, GE gastro-esophageal, NVC nailfold videocapillaroscopy, VEGF-A vascular endothelial growth factor A, sPAP systolic pulmonary artery pressure on echocardiography, SSc systemic sclerosis; vs: versus, ACA anti-centromere
  2. * p < 0.05